Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An Update on Vaginal Microbicides.

Christine Mauck1, Gustavo Doncel

  • 1CONRAD Program, 1611 North Kent Street, Arlington, VA 22209, USA. cmauck@conrad.org

Current Infectious Disease Reports
|November 28, 2001
PubMed
Summary

Developing topical microbicides is crucial for preventing sexually transmitted infections (STIs), including AIDS. This research reviews current microbicide development, ideal properties, and future prospects for these vital infection-prevention compounds.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Comparison of F/TAF and F/TDF as HIV Pre-Exposure Prophylaxis in a Predominantly Cisgender Women Population in East and South Africa: A Randomized, Factorial, Noninferiority Trial.

Journal of acquired immune deficiency syndromes (1999)·2026
Same author

Safety testing of Ovaprene: An investigational nonhormonal monthly vaginal contraceptive.

Contraception·2024
Same author

Successful postcoital testing of Ovaprene: An investigational non-hormonal monthly vaginal contraceptive.

Contraception·2024
Same author

A phase 1/2, open-label, parallel group study to evaluate the preliminary efficacy and usability DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal RinGSM) over 12 weeks in healthy postmenopausal women.

Menopause (New York, N.Y.)·2023
Same author

A phase 1/2, open-label, parallel group study to evaluate the safety and pharmacokinetics of DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal rings) over 12 weeks in healthy postmenopausal women.

Menopause (New York, N.Y.)·2023
Same author

Acceptability of Single-dose Clindamycin Gel for Bacterial Vaginosis: A Randomized Controlled Trial.

Clinical therapeutics·2023

Area of Science:

  • Virology
  • Immunology
  • Pharmacology

Background:

  • Rising rates of sexually transmitted diseases (STDs), particularly AIDS, necessitate enhanced prevention strategies.
  • Topical microbicides are being developed as a key approach to prevent mucosal infections by STD pathogens.

Purpose of the Study:

  • To provide an update on microbicide research and development.
  • To discuss preclinical screening, ideal microbicide properties, current candidates, and future directions.

Main Methods:

  • Review of preclinical screening algorithms for microbicide candidates.
  • Analysis of essential properties for effective microbicides.
  • Identification and overview of compounds currently in the development pipeline.

Main Results:

  • Numerous microbicide candidates are in preclinical development.
  • A limited number have undergone safety testing, with even fewer progressing to clinical efficacy trials.

Conclusions:

  • Microbicide development is a critical area of research for STD prevention.
  • Further research and clinical trials are essential to advance promising candidates towards public health application.

Related Experiment Videos